Patents by Inventor Frederick L. Baehner

Frederick L. Baehner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method to Use Gene Expression to Determine Likelihood of Clinical Outcome of Renal Cancer
    Publication number: 20240096451
    Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
    Type: Application
    Filed: August 23, 2023
    Publication date: March 21, 2024
    Applicant: Genomic Health, Inc.
    Inventors: Wayne Cowens, Steven SHAK, Audrey GODDARD, Dejan KNEZEVIC, Joffre Baker, Michael C. Kiefer, Tara MADDALA, Frederick L. Baehner
  • Method to use gene expression to determine likelihood of clinical outcome of renal cancer
    Patent number: 11776664
    Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: October 3, 2023
    Assignee: Genomic Health, Inc.
    Inventors: Wayne Cowens, Steven Shak, Audrey Goddard, Dejan Knezevic, Joffre Baker, Michael C. Kiefer, Tara Maddala, Frederick L. Baehner
  • METHOD FOR USING GENE EXPRESSION TO DETERMINE PROGNOSIS OF PROSTATE CANCER
    Publication number: 20220396842
    Abstract: The present disclosure includes assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for the patient, and likelihood that the patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status.
    Type: Application
    Filed: August 19, 2022
    Publication date: December 15, 2022
    Inventors: Steven SHAK, Frederick L. Baehner, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER
  • Method to Use Gene Expression to Determine Likelihood of Clinical Outcome of Renal Cancer
    Publication number: 20220051755
    Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
    Type: Application
    Filed: November 19, 2020
    Publication date: February 17, 2022
    Applicant: Genomic Health, Inc.
    Inventors: Wayne COWENS, Steven SHAK, Audrey GODDARD, Dejan KNEZEVIC, Joffre BAKER, Michael C. KIEFER, Tara MADDALA, Frederick L. BAEHNER
  • Method to Use Gene Expression to Determine Likelihood of Clinical Outcome of Renal Cancer
    Publication number: 20210166790
    Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
    Type: Application
    Filed: November 19, 2020
    Publication date: June 3, 2021
    Applicant: Genomic Health, Inc.
    Inventors: Wayne COWENS, Steven SHAK, Audrey GODDARD, Dejan KNEZEVIC, Joffre BAKER, Michael C. KIEFER, Tara MADDALA, Frederick L. BAEHNER
  • Method to use gene expression to determine likelihood of clinical outcome of renal cancer
    Patent number: 10892038
    Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: January 12, 2021
    Assignee: Genomic Health, Inc.
    Inventors: Wayne Cowens, Steven Shak, Audrey Goddard, Dejan Knezevic, Joffre Baker, Michael C. Kiefer, Tara Maddala, Frederick L. Baehner
  • Method for Using Gene Expression to Determine Prognosis of Prostate Cancer
    Publication number: 20200255911
    Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
    Type: Application
    Filed: February 25, 2020
    Publication date: August 13, 2020
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Steven SHAK, Frederick L. BAEHNER, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER
  • Method for Using Gene Expression to Determine Prognosis of Prostate Cancer
    Publication number: 20190249260
    Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
    Type: Application
    Filed: February 22, 2019
    Publication date: August 15, 2019
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Steven SHAK, Frederick L. BAEHNER, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER
  • Method for using gene expression to determine prognosis of prostate cancer
    Patent number: 10260104
    Abstract: The present disclosure includes assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for the patient, and likelihood that the patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: April 16, 2019
    Assignee: Genomic Health, Inc.
    Inventors: Steven Shak, Frederick L. Baehner, Tara Maddala, Mark Lee, Robert J. Pelham, Wayne Cowens, Diana Cherbavaz, Michael C. Kiefer, Michael Crager, Audrey Goddard, Joffre B. Baker
  • METHOD TO USE GENE EXPRESSION TO DETERMINE LIKELIHOOD OF CLINICAL OUTCOME OF RENAL CANCER
    Publication number: 20170121780
    Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
    Type: Application
    Filed: December 5, 2016
    Publication date: May 4, 2017
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Wayne COWENS, Steven SHAK, Audrey GODDARD, Dejan KNEZEVIC, Joffre BAKER, Michael C. KIEFER, Tara MADDALA, Frederick L. BAEHNER
  • Method to use gene expression to determine likelihood of clinical outcome of renal cancer
    Patent number: 9551034
    Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: January 24, 2017
    Assignee: Genomic Health, Inc.
    Inventors: Wayne Cowens, Steven Shak, Audrey Goddard, Dejan Knezevic, Joffre Baker, Michael C. Kiefer, Tara Maddala, Frederick L. Baehner
  • METHOD FOR USING GENE EXPRESSION TO DETERMINE PROGNOSIS OF PROSTATE CANCER
    Publication number: 20160097105
    Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
    Type: Application
    Filed: October 20, 2015
    Publication date: April 7, 2016
    Applicant: GENOMIC HEALTH, INC.
    Inventors: Steven SHAK, Frederick L. BAEHNER, Tara MADDALA, Mark LEE, Robert J. PELHAM, Wayne COWENS, Diana CHERBAVAZ, Michael C. KIEFER, Michael CRAGER, Audrey GODDARD, Joffre B. BAKER
  • METHOD FOR USING GENE EXPRESSION TO DETERMINE PROGNOSIS OF PROSTATE CANCER
    Publication number: 20120028264
    Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
    Type: Application
    Filed: July 25, 2011
    Publication date: February 2, 2012
    Inventors: Steven Shak, Frederick L. Baehner, Tara Maddala, Mark Lee, Robert J. Pelham, Wayne Cowens, Diana Cherbavaz, Michael C. Kiefer, Michael Crager, Audrey Goddard, Joffre B. Baker
  • METHOD TO USE GENE EXPRESSION TO DETERMINE LIKELIHOOD OF CLINICAL OUTCOME OF RENAL CANCER
    Publication number: 20110171633
    Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
    Type: Application
    Filed: January 7, 2011
    Publication date: July 14, 2011
    Inventors: Wayne Cowens, Steven Shak, Audrey Goddard, Dejan Knezevic, Joffre B. Baker, Michael C. Kiefer, Tara Maddala, Frederick L. Baehner
  • Method for Determining the Likelihood of Response to HER2 Inhibitors
    Publication number: 20100151463
    Abstract: The present disclosure provides methods for determining the HER2 Status of a cancer tumor sample.
    Type: Application
    Filed: September 4, 2009
    Publication date: June 17, 2010
    Inventors: Frederick L. Baehner, Drew Watson, Tara Maddala, Steve Shak, Robert Gray, Joseph Sparano